Staphylococcus aureus in Atopic Dermatitis: Past, Present, and Future.
Anti-Bacterial Agents
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ therapeutic use
Bacterial Vaccines
/ therapeutic use
Bridged Bicyclo Compounds, Heterocyclic
/ therapeutic use
Dermatitis, Atopic
/ microbiology
Dermatologic Agents
/ therapeutic use
Diterpenes
/ therapeutic use
Dysbiosis
/ complications
Filaggrin Proteins
Humans
Laurates
/ therapeutic use
Microbiota
Monoglycerides
/ therapeutic use
Probiotics
/ therapeutic use
Skin
/ microbiology
Staphylococcal Infections
/ complications
Staphylococcus aureus
Surface-Active Agents
/ therapeutic use
Symptom Flare Up
Journal
Dermatitis : contact, atopic, occupational, drug
ISSN: 2162-5220
Titre abrégé: Dermatitis
Pays: United States
ID NLM: 101207335
Informations de publication
Date de publication:
Historique:
pubmed:
27
3
2020
medline:
6
5
2021
entrez:
27
3
2020
Statut:
ppublish
Résumé
: The role of Staphylococcus aureus (SA) in the pathogenesis and management in atopic dermatitis is rapidly evolving. The modern understanding of SA in atopic dermatitis now includes an expanded array of virulence factors, the interplay of clonal and temporal shifts in SA populations, and host factors such as filaggrin and natural moisturizing factor. New, emerging therapies that focus on long-term, targeted elimination of SA colonization are currently under investigation (Br J Dermatol 2017;17(1)63-71). Herein, we discuss and review the latest staphylococcal and microbiome-modifying therapies including topical antibiotics, topical natural oil fatty acids, anti-SA vaccines, microbial transplantation, vitamin D supplementation, dupilumab and proposed future investigative directions.
Identifiants
pubmed: 32209864
doi: 10.1097/DER.0000000000000589
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antibodies, Monoclonal, Humanized
0
Bacterial Vaccines
0
Bridged Bicyclo Compounds, Heterocyclic
0
Dermatologic Agents
0
Diterpenes
0
FLG protein, human
0
Filaggrin Proteins
0
Laurates
0
Monoglycerides
0
Surface-Active Agents
0
monolaurin
27215-38-9
dupilumab
420K487FSG
retapamulin
4MG6O8991R
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM